Clinical experience with idarucizumab prior to thrombolytic therapy of cerebral infarction in the Sverdlovsk region
https://doi.org/10.52420/2071-5943-2021-20-4-73-77
Abstract
Introduction. In recent years, the use of oral anticoagulants for the prevention of ischemic strokes (IS) in patients with atrial fibrillation (AF), as well as the prevention of deep vein thrombosis and thromboembolism has been increasing in clinical practice. According to epidemiological studies, ischemic strokes account for about 85% of all AMI. Cardioembolic strokes (CES), which develop due to embolism to the cerebral vessels from the heart chambers, deserve special attention. The presence of AF is associated with a twofold increase in the risk of death from cardiovascular disease and death from any cause. Timely anticoagulant therapy can reduce the risk of thromboembolic complications and improve the prognosis.
Materials and Methods. The authors present a clinical observation in which a 47-year-old female patient diagnosed with venous insufficiency, who took dabigatran 150 mg twice a day for a year, developed IS with left-sided pronounced hemiparesis. After 170 minutes from the development of the stroke, idarucizumab was administered to neutralize the anticoagulant effect of dabigatran and thrombolytic therapy (TLT) was performed.
Results. Twenty-four hours after TLT, the National Institutes of Health Stroke Scale (NIHSS) score decreased from 16 to 6. A repeat CT scan of the brain revealed a focus of ischemia in the right frontal, parietal, and temporal lobes. On the 19th day of the AI, dabigatran 150 mg 2 times a day was resumed.
Conclusion. The presented observation confirms that in patients with AI developed against the background of dabigatran, the administration of idarucizumab is safe and allows for TLT.
About the Authors
N. V. Yurovskikh
Kamensk-Uralsky City Hospital
Russian Federation
Russian Federation
Nadezhda V. Yurovskikh
Kamensk-Uralsk
G. V. Jarygina
Kamensk-Uralsky City Hospital
Russian Federation
Russian Federation
Galina V. Jarygina
Kamensk-Uralsk
References
1. Клинические Рекомендации: «Диагностика и лечение фибрилляции предсердий», 2017 г. РКО, рабочая группа по разработке рекомендаций «Диагностика и лечение фибрилляции предсердий» акад. РАН Ревишвили А.Ш. (г. Москва), акад. РАН Шляхто Е.В. (г. Санкт-Петербург)
2. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association, Stroke. 2018;49:eXXX–eXXX. DOI: 10.1161/STR.0000000000000158.
3. Blood / Schiele et al. – 2013;121:3554–62.
4. Stangier et al. OR 320; представлено на ISTH 2015
5. Прадакса®: КХЛП, 2017
6. Thromb Haemost / Schmohl et al. – 2017;117:269–76.
7. J. Steffel et al. // European Heart Journal (2018) 00, 1–64 doi:10.1093/eurheartj/ehy136
8. Первый опыт тромболитической терапии инфаркта мозга в Российской Федерации после применения идаруцизумаба / Пудов Е. В., Сухачева Н. Н., Петелина И. С. // Неврология, нейропсихиатрия, психосоматика. 2020;12(1):68–71.
9. Реперфузионная терапия ишемического инсульта. Клинический протокол. Москва; 2019. 80 с. [Reperfuzionnaya terapiya ishemich— eskogo insul'ta. Klinicheskiiprotokol [Reperfusion therapy for ischemic stroke. Clinical protocol]. Moscow; 2019. 80 p.] https://medknigaservis.ru/wp-content/uploads/2019/06/NF0014418.pdf.
10. Thrombolysis and thrombectomyin patients treated with dabigatranwith acute ischemic stroke: expert opinion / Diener H. C., Bernstein R., Butcher K. et al. // Int J Stroke. 2017 Jan; 12(1):9-12. doi: 10.1177/1747493016669849.
11. Idarucizumab for dabigatran reversal-full cohort / Pollack Jr. C. V., Reilly P. A., van Ryn J. et al.
12. Idarucizumab in dabiga — tran-treated patients with acute ischemic stroke receiving Alteplase: a systematic review of the available evidence / Pikija S., Sztriha L. K., Sebastian Mutzenbach J. et al. // CNSDrugs. 2017 Sep;31(9): 747-757. – doi: 10.1007/s40263-017-0460-x.
13. Kermer, P., Eschenfelder CC, Diener HC, et al. Antagonizing dabigatran by idarucizumabin cases of ischemictroke or intracranial hemorrhage in Germany — a national case collection // Int J Stroke. 2017 Jun;12(4):383-391. doi: 10.1177/1747493017701944.
14. Intravenous thrombolysis in patientswith acuteischemic stroke after areversal of dabigatran anticoagulation with idarucizumab / Sanak D., Jakubicek S., Cernik D. et al. // J Neurol Neurosurg Psychiatry. – 2018 May;89(5): 549-550. – doi: 10.1136/jnnp-2017-316449.
15. Intravenous thrombolysis in acute ischemic strokeafteridarucizumabreversal of dabigatran effect: Analysis of the cases from Taiwan / Fang C. W., Tsai Y. T., Chou P. C. et al. // J Stroke Cerebrovasc Dis. 2019 Mar;28(3): 815-820. doi: 10.1016/j.jstrokecerebrovas—dis.2018.11.029. Epub 2018 Dec 17.
16. Connolly SJ et al. N Engl J Med 2009;361:1139–51; Connolly SJ et al. N Engl J Med 2010;363:1875–6; Patel MR et al. N Engl J Med 2011;365:883–91; Granger C et al. N Engl J Med 2011;365:981–92; Pradaxa; EU, SmpC, доступно по ссылке http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf 09 августа 2017
17. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association, Stroke. 2018;49:eXXX–eXXX. DOI: 10.1161/STR.0000000000000158., Diener H-C et al; International Journal of Stroke 0(0) 1–4, J. Steffel et al; European Heart Journal (2018) 00, 1–64 doi:10.1093/eurheartj/ehy136
18. Эндоваскулярное лечение тандемной острой окклюзии внутренней сонной и средней мозговой артерии при остром ишемическом инсульте / Хрипун А. И., Миронков А. Б., Лихарев А .Ю. и др. // Неврология и психиатрия им. С.С. Корсакова. – Том 119, 3-2, 2019.
19. Новые оральные антикоагулянты (дабигатран) или варфарин? Преимущества и недостатки / Буланов А. А., Солуданов Д. А. // Сборник трудов конференции «Инновации в диагностике и лечении пациентов с неврологическими заболеваниями. От науки к практике», г. Пенза, 27 апреля 2019 г.
Review
For citations:
Yurovskikh NV, Jarygina GV. Clinical experience with idarucizumab prior to thrombolytic therapy of cerebral infarction in the Sverdlovsk region. Ural Medical Journal. 2021;20(4):73-77. (In Russ.) https://doi.org/10.52420/2071-5943-2021-20-4-73-77
Views:
267
Email this article 